Skip to main content

CR Bard To Pay $250K In 2nd Hernia Mesh Bellwether

CR Bard To Pay $250K In 2nd Hernia Mesh Bellwether

CR Bard To Pay $250K In 2nd Hernia Mesh Bellwether

Introduction

A man who alleged C.R. Bard of designing a defective hernia mesh patch has been awarded $250,000 in the second bellwether trial from the multidistrict litigation over hernia mesh products.

The verdict in the trial has been awarded on the 18th day of trial after the jury rejected products liability, failure to warn, negligent misrepresentation and fraudulent misrepresentation claims.

The plaintiff in the lawsuit had got a Ventralex Hernia Patch implanted in July 2007, as mentioned in the complaint. He had to undergo several surgeries due to the patch. The plaintiff filed a suit, along with his spouse, who was awarded $5,000 in loss of consortium damages.

The plaintiff's attorney, over and over, told the jury that Bard's Ventralex is still on the market, which is unfair as it is defective in design. The jury responded by stating that the court is aware of the defective design of the patch and it is glad that the plaintiff dared to report the issue which has resulted in this immportant verdict.

The first bellwether trial held in Ohio was awarded in the favor of Bard and its subsidiary Davol where the jury did not find the company responsible for the injuries sustained by the plaintiff due to Ventralight ST hernia mesh.

According to the  Judicial Panel on Multidistrict Litigation, it is the third biggest MDL in the country that involves nearly 16,700 pending cases over the Bard products.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!